Relapse of proteinuria · people IgA nephropathy
Tonsillectomy plus standard care may leads to lower relapse of proteinuria compared with standard care (low certainty).
1 finding from 1 review
> 50% increase in SCr · people IgA nephropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proteinuria · people IgA nephropathy
1 finding from 1 review
Complete remission of proteinuria · people IgA nephropathy
Renin‐angiotensin system inhibition showed no clear difference in remission of proteinuria: complete remission compared with placebo or no treatment (low certainty).
1 finding from 1 review
Remission of haematuria · people IgA nephropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse of proteinuria · people IgA nephropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
> 50% increase in SCr · people IgA nephropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proteinuria · people IgA nephropathy
1 finding from 1 review
Death · people IgA nephropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Kidney failure · people IgA nephropathy
It is very uncertain whether renin‐angiotensin system inhibition changes kidney failure compared with other supportive care treatment (very low certainty).
1 finding from 1 review
All‐cause mortality · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes all‐cause mortality compared with morning dosing regimen (very low certainty).
1 finding from 1 review
Cardiovascular mortality · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular morbidity · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes serious adverse events compared with morning dosing regimen (very low certainty).
1 finding from 1 review
Overall adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes overall adverse events compared with morning dosing regimen (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes withdrawals from treatment due to adverse events compared with morning dosing regimen (very low certainty).
1 finding from 1 review
Death (fetal, neonatal, or later (up to 2 years' corrected age))** · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death (fetal, neonatal, or later (up to 2 years' corrected age))** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Death or cerebral palsy · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death or cerebral palsy (up to school age)** compared with placebo (outcomes (low certainty).
2 findings from 1 review
Major neurodevelopmental disability at childhood · women at risk of preterm birth (< 34 weeks' gestation)
It is very uncertain whether magnesium sulphate changes major neurodevelopmental disability (school age)** compared with placebo (outcomes (very low certainty).
1 finding from 1 review
Death or major neurodevelopmental disability · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death or major neurodevelopmental disability (up to school age)** compared with placebo (outcomes (low certainty).
2 findings from 1 review